In vitro thrombogenicity assessment evaluates the tendency of blood-contacting medical devices and biomaterials to induce thrombus formation under controlled laboratory conditions, serving as a core element of the hemocompatibility evaluation defined in ISO 10993-4. This testing is essential for regulatory submissions, biological safety risk management, and the development of cardiovascular, extracorporeal circulation, and transfusion products. This article provides a comprehensive overview of the principles, sample types, test items, methodologies, and applications of in vitro thrombus formation tendency evaluation.
Technical Overview
In vitro thrombogenicity assessment is a laboratory-based biological evaluation that quantifies the propensity of a medical device, material, or surface coating to trigger thrombus (blood clot) formation upon contact with blood. When blood encounters a foreign surface, plasma proteins such as fibrinogen and von Willebrand factor adsorb rapidly onto the material, followed by platelet adhesion, activation, and aggregation, as well as activation of the intrinsic coagulation cascade. The resulting thrombin generation and fibrin network formation can produce occlusive clots, embolic fragments, and depletion of platelets and coagulation factors, all of which pose serious clinical risks to patients.
The evaluation is governed primarily by ISO 10993-4 (Biological evaluation of medical devices – Part 4: Selection of tests for interactions with blood), which classifies blood-contacting devices according to contact category (external communicating devices, implants) and contact duration (limited, prolonged, permanent), and specifies five test categories: thrombosis, coagulation, platelets, hematology, and the complement system. Supporting standards include ISO 10993-1 for risk-based test planning, ISO 10993-12 for sample preparation, ISO 10993-2 for animal welfare justification, ASTM F2382 for in vitro measurement of thrombogenicity of medical devices and materials, ASTM F1830 for blood selection in in vitro evaluations, and GB/T 16886.4, the Chinese national adoption of ISO 10993-4.
Compared with in vivo models such as the non-anticoagulated venous implant (NAVI) study, in vitro thrombogenicity testing offers highly controlled and quantitative conditions, excellent sensitivity for discriminating between materials, lower cost, and a significantly reduced burden of animal testing. It is therefore widely used as a first-line screening tool and as supporting evidence within an overall biological safety evaluation file prepared by accredited third-party laboratories.
Testing Samples
Intravascular and Cardiovascular Devices
Devices that are intended for direct contact with circulating blood represent the primary category of test articles. Typical samples include:
- Coronary and peripheral vascular stents, including bare-metal, drug-eluting, and bioresorbable scaffolds
- Vascular grafts, stent grafts, and artificial blood vessels
- Central venous catheters, peripherally inserted central catheters (PICC), hemodialysis catheters, and umbilical catheters
- Guidewires, balloon dilation catheters, and thrombectomy catheters
- Heart valve prostheses, septal occluders, inferior vena cava filters, and ventricular assist device blood-contacting components
Extracorporeal Circulation and Blood-Handling Devices
Products used in extracorporeal circuits experience prolonged blood contact under dynamic shear conditions and require dedicated thrombogenicity evaluation:
- Membrane oxygenators and extracorporeal membrane oxygenation (ECMO) circuit sets
- Hemodialyzers, hemoperfusion cartridges, and plasmapheresis filters
- Blood tubing sets, cannulae, reservoirs, and cardiotomy suction devices
- Blood pumps, ventricular assist devices, and intra-aortic balloon pumps
- Autotransfusion and cell salvage systems
Transfusion, Infusion, and Blood Storage Products
These devices contact blood or blood components during collection, storage, and administration, including blood collection bags, blood administration and transfusion sets, infusion sets, syringes, and needle-free connectors.
Raw Materials, Coatings, and Test Coupons
Material-level screening is commonly performed on polymer films, metal coupons, tubing segments, and surface-modified samples such as heparin-coated, hydrophilic-coated, or antithrombotic-modified surfaces. In all cases, samples should represent the final product in its sterilized, finished state. According to ISO 10993-12, testing typically requires multiple production lots (commonly three), defined surface-area-to-extraction-volume ratios, and documented handling, cleaning, and sterilization conditions to ensure representative and reproducible results.
Testing Items
The selection of test endpoints depends on the device category, blood contact duration, and intended use. Core in vitro thrombogenicity parameters include:
- Whole blood clotting time and recalcified clotting time (modified Lee-White method) for static thrombus formation tendency
- Thrombus mass (wet and dry weight), thrombus formation index, and percent thrombus surface coverage
- Lumen occlusion rate and flow maintenance rate in dynamic perfusion models
- Platelet count, platelet count reduction, and platelet adhesion density per unit surface area
- Platelet activation markers: P-selectin (CD62P) expression, PAC-1 binding, beta-thromboglobulin, and platelet factor 4 (PF4)
- Coagulation activation markers: activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen, thrombin-antithrombin (TAT) complex, prothrombin fragment F1+2, fibrinopeptide A, and D-dimer
- Complement activation markers (C3a, C5a, SC5b-9) and leukocyte counts as optional hemocompatibility endpoints
- Morphological evaluation by scanning electron microscopy (SEM), including platelet morphology scoring (resting, dendritic, spread, fully activated forms), fibrin deposition, and red blood cell entrapment
- Gravimetric and image-analysis quantification of thrombus burden on device surfaces and within lumens
Testing Methods
Static Direct-Contact Clotting Time Test
In this simplified screening method, fresh non-anticoagulated blood or recalcified citrated blood is brought into direct contact with the test material at 37°C, and the time required for visible clot formation is recorded. Prolonged clotting times indicate a lower thrombus formation tendency. A graded clotting profile obtained by terminating contact at serial time points allows semi-quantitative comparison against reference materials and is suitable for early material screening.
Modified Chandler Loop Test
The Chandler loop is one of the most widely applied dynamic in vitro models. Test samples are mounted inside closed polymeric tubing loops filled with recalcified citrated blood, and the loops are rotated around a horizontal axis at 37°C to generate a continuous blood flow over the surfaces. Following incubation, thrombus mass, residual platelet counts, and coagulation markers are quantified. This method follows the general principles described in ASTM F2382 and provides strong discrimination between materials with different thrombogenic potentials.
Dynamic Flow Loop and Pulsatile Perfusion Model
For devices intended to operate under physiological flow and shear, such as oxygenators, dialyzers, and blood pumps, a recirculating flow loop driven by a peristaltic or pulsatile pump is established. Heparinized or minimally anticoagulated blood is circulated through the test device at defined flow rates and durations, while endpoints such as thrombus weight, pressure drop across the device, platelet consumption, TAT complex generation, and flow maintenance are monitored continuously or at scheduled intervals. Blood selection and handling for such evaluations follow guidance such as ASTM F1830.
Platelet Adhesion and Activation Assays
Platelet-rich plasma or whole blood is incubated with test coupons under static or agitated conditions. After washing and fixation, adhered platelets are quantified by microscopy, fluorescence labeling, scanning electron microscopy, or lactate dehydrogenase (LDH) release assay. Flow cytometric detection of P-selectin and PAC-1 binding on circulating platelets provides sensitive markers of platelet activation induced by the test surface.
Blood Source, Anticoagulation, and Controls
Human donor blood is preferred where ethically and practically feasible, as it best reflects clinical conditions; otherwise animal blood (canine, ovine, porcine, or bovine) may be justified with documented rationale. Anticoagulation strategies, such as citrate recalcification or controlled heparinization, must be matched to the test model. Each study includes a negative control (for example, a medical-grade reference polymer), a positive thrombogenic control (such as glass, latex, or collagen), and adequate replication across donors and lots to support statistical comparison. All procedures follow documented protocols under quality management systems in accredited third-party laboratories.
Applications
In vitro thrombogenicity assessment supports the entire product lifecycle of blood-contacting medical devices:
- Regulatory submission support, including biological evaluation reports for ISO 10993-1-based risk assessments and market authorization dossiers in major jurisdictions
- Research and development screening of candidate polymers, metals, and ceramics prior to animal testing
- Optimization and verification of antithrombotic surface coatings, such as heparinized, hydrophilic, and zwitterionic coatings
- Design change control, process modification validation, and comparability studies
- Supplier qualification, raw material substitution assessment, and batch consistency monitoring
- Scientific publication and benchmarking against competitor devices and state-of-the-art reference materials
- Risk management documentation under ISO 14971, demonstrating that thrombosis-related residual risks are acceptable
FAQ
When is in vitro thrombogenicity assessment required?
ISO 10993-4 requires blood interaction testing for any device with direct contact with circulating blood, including external communicating devices and implants. For devices with indirect blood contact or transient contact, a rationale-based evaluation may suffice, but a documented scientific justification is always necessary.
Should I choose a static or dynamic test method?
Static clotting time tests are appropriate for rapid material screening, while dynamic models such as the Chandler loop or flow loop better simulate clinical shear stress and are preferred for final product verification, particularly for intravascular and extracorporeal circulation devices.
Is human or animal blood preferred for testing?
Human donor blood provides the most clinically relevant results and is preferred whenever available. Animal blood may be used where human blood is impractical, provided species differences are justified and documented in the test protocol.
What are the acceptance criteria?
There is no universal pass-fail threshold in the standards. Thrombogenicity is judged comparatively against negative and positive controls and, where available, clinical reference devices, with results interpreted through the overall risk assessment process defined by ISO 10993-1 and ISO 14971.
Can in vitro results replace in vivo thrombogenicity testing?
In vitro data are powerful for screening and material comparison but generally do not fully replace in vivo studies for high-risk implant devices. ISO 10993-4 encourages in vitro testing first to minimize animal use, with in vivo studies reserved for cases where in vitro results are inconclusive or where regulatory expectations require them.
How many samples and donors are needed?
Typical protocols use at least three production lots of the final sterilized product and blood from multiple independent donors (commonly three or more) to address biological variability, with replicate test and control articles per condition as specified in the study plan.